HOWARD WEINER to Disease-Free Survival
This is a "connection" page, showing publications HOWARD WEINER has written about Disease-Free Survival.
Connection Strength
0.082
-
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler. 2014 Sep; 20(10):1381-90.
Score: 0.023
-
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24; 380(9856):1819-28.
Score: 0.020
-
Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010 Sep; 12(9):985-90.
Score: 0.017
-
Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol. 2004 Dec 15; 22(24):4881-7.
Score: 0.012
-
Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol Oncol. 2003 May; 25(5):372-8.
Score: 0.010